Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands

Autor: Hans Rümke, Hester E. de Melker, Dominic Thorrington, Mirjam J. Knol, Leo G. van Rossum, Albert Jan van Hoek, Eelko Hak
Přispěvatelé: Microbes in Health and Disease (MHD), PharmacoTherapy, -Epidemiology and -Economics, Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
Rok vydání: 2018
Předmět:
Pediatrics
Pulmonology
Economics
Cost effectiveness
Cost-Benefit Analysis
lcsh:Medicine
Social Sciences
Geographical locations
Pneumococcal Vaccines
Families
Elderly
0302 clinical medicine
Community-acquired pneumonia
Epidemiology
Medicine and Health Sciences
Public and Occupational Health
030212 general & internal medicine
lcsh:Science
Children
Netherlands
Vaccines
Multidisciplinary
Cost-effectiveness analysis
Middle Aged
Vaccination and Immunization
3. Good health
Europe
Vaccination
Infectious Diseases
Quality-Adjusted Life Years
Infants
CONJUGATE VACCINE
Research Article
medicine.medical_specialty
Infectious Disease Control
Immunology
Cost-Effectiveness Analysis
030231 tropical medicine
complex mixtures
Pneumococcal Infections
03 medical and health sciences
Conjugate vaccine
medicine
Journal Article
Humans
European Union
OLDER-ADULTS
Aged
business.industry
lcsh:R
Infant
Biology and Life Sciences
Pneumonia
medicine.disease
Pneumococcal polysaccharide vaccine
Economic Analysis
Quality-adjusted life year
Geriatrics
Age Groups
People and Places
lcsh:Q
Population Groupings
Preventive Medicine
business
Zdroj: PLOS ONE
PLoS ONE
PLoS ONE, Vol 13, Iss 2, p e0192640 (2018)
PLoS ONE, 13(2):e0192640. PUBLIC LIBRARY SCIENCE
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0192640
Popis: BACKGROUND: Streptococcus pneumoniae causes morbidity and mortality among all ages in The Netherlands. To reduce this burden, infants in The Netherlands receive the 10-valent pneumococcal conjugated vaccine (PCV10), but older persons are not targeted. We assessed the impact and cost-effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23) or 13-valent PCV (PCV13) among all those aged 60, 65 or 70 and/or in combination with replacing PCV10 with PCV13 in the infant vaccination programme.METHODS: A static cost-effectiveness model was parameterized including projected trends for invasive pneumococcal disease (IPD) and hospitalised community acquired pneumonia (CAP). The different strategies were evaluated using vaccine list prices and a 10-year time horizon. Incremental cost-effectiveness ratios (ICER) were calculated with the current strategy (infant vaccination program with PCV10) as reference.RESULTS: Compared to the reference, the largest impact on pneumococcal disease burden was projected with a combined use of PCV13 among infants and PPV23 at 60, 65 and 70 years, preventing 1,635 cases of IPD and 914 cases of CAP. The most cost-effective strategy was vaccinating with PPV23 at 70 years only with similar low ICERs at age 60 and 65. The impact of the use of PCV13 among infants depends strongly on the projected herd-immunity effect on serotype 19A. Vaccinating elderly with either PCV13 or PPV23 was dominated by PPV23 in all investigated scenarios, mainly due to the lower price of PPV23.CONCLUSION: Under the current assumptions, the best value for money is the use of PPV23 for elderly, with a single dose or at five year increment between age 60 to age 70.
Databáze: OpenAIRE
Externí odkaz: